To characterize the oral bacterial microbiome in HIV-infected participants at baseline and after 24 weeks of EFV/FTC/TDF.
Thirty-five participants co-enrolled in two AIDS Clinical Trials Group (ACTG) studies, A5272 and A5280, with paired saliva samples and complete data sets were assessed.
Paired saliva samples were evaluated for bacterial microbiome using 16S rDNA PCR followed by Illumina sequencing. Diversity and differential abundance was compared between groups. A random forest classification scheme was used to determine the contribution of parameters in classifying participants’ CD4+ T-cell count.
Bacterial communities demonstrated considerable variability both within participants and between timepoints, although they became more similar after 24 weeks of ART. At baseline, both the number of taxa detected and the average alpha diversity were variable between participants, but did not differ significantly based on CD4+ cell count, viral load or other factors. After 24 weeks of ART samples obtained from participants with persistently low CD4+ T-cell counts had significantly higher bacterial richness and diversity. Several differentially abundant taxa, including Porphyromonas species associated with periodontal disease, were identified, which discriminated between baseline and posttreatment samples. Analysis demonstrated that although inflammatory markers are important in untreated disease, the salivary microbiome may play an important role in CD4+ T-cell count recovery after ART.
Shifts in the oral microbiome after ART initiation are complex, and may play an important role in immune function and inflammatory disease.
aWashington University School of Medicine, St. Louis, Missouri
bCase Western Reserve, Cleveland, Ohio
cUniversity of California, San Francisco, San Francisco, California
dUniversity of North Carolina, Chapel Hill, North Carolina
eJohn Hopkins University, Baltimore, Maryland
fColumbia University Medical Center, New York, New York
gUniversity of Alabama, Birmingham, Alabama, USA.
Correspondence to Rachel M. Presti, MD, PhD, Washington University School of Medicine, 4523 Clayton Ave, Box 8051, St. Louis, MO 63110, USA. E-mail: firstname.lastname@example.org
Received 18 October, 2017
Revised 5 January, 2018
Accepted 9 January, 2018
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).